Name: Panchamoorthy, Govind Position Title: Vice President, Immuno-oncology Organization and Location:XYone Threpeutics, Canton, Massachusetts, United States PROFESSIONAL PREPARATION: INSTITUTION AND LOCATION DEGREE Start Date Completion Date FIELD OF STUDY Zeneca Pharmaceuticals, Wilmington, Delaware, United States Postdoctoral Fellow 04/1997 - 12/1999 Target Discovery & Validation Brigham & Women’s Hospital, Boston, Massachusetts, United States Postdoctoral Fellow 01/1992 - 04/1997 Immunological Signal Transduction Dana Farber Cancer Institute, Boston, Massachusetts, United States Postdoctoral Fellow 01/1990 - 12/1991 Antigen recognition by gamma/delta T cells Education: All India Institute of Medical Sciences, New Delhi, India Ph.D. 06/1984 - 12/1988 Immunochemistry Jawaharlal Nehru University, New Delhi, India M.Sc. 06/1980 - 05/1982 Life Sciences Government Art College, Villupuram, University of Madras, Villupuram, India B.Sc. 06/1977 - 05/1980 Chemistry, Physics & Mathematics Appointments and Positions: 2022 - present Vice President, Immuno-oncology, XYone Threpeutics, Canton, Massachusetts, United States 2019 - 2022 Director, Discovery Research, Genus Oncology, LLC., Boston, Massachusetts, United States 2016 - 2018 Director, Biotherapeutics, Genus Oncology, LLC., Boston, Massachusetts, United States 2008 - 2016 Principal Scientist & Group Leader, Genus Oncology, LLC., Boston, Massachusetts, United States 2006 - 2008 R&D Scientist II, Massachusetts Biologic Laboratories, UMass Medical Center, Mattappan, Massachusetts, United States 2003 - 2006 Validation Manager, Analytical Support & Improvement, Sanfi Pasteur, Swiftwater, PA, United States 2001 - 2003 Lab Head Scientist, AstraZeneca R&D Boston, Waltham, Massachusetts, United States 2000 - 2001 Scientist, AstraZenenca, Wilmington, Delaware, United States Products: Products Closely Related to the Proposed Project 1. Panchamoorthy G, Jin C, Raina D, Bharti A, Yamamoto M, Adeebge D, Zhao Q, Bronson R, Jiang S, Li L, Suzuki Y, Tagde A, Ghoroghchian PP, Wong KK, Kharbanda S, Kufe D. Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. JCI Insight. 2018 Jun 21;3(12) PubMed Central PMCID: PMC6124453. Other Significant Products Highlighting Contributions to Science 1. Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J, Kufe D. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene. 2014 Jun 26;33(26):3422-31. PubMed Central PMCID: PMC3916940. 2. Raina D, Ahmad R, Rajabi H, Panchamoorthy G, Kharbanda S, Kufe D. Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol. 2012 May;40(5):1643-9. PubMed Central PMCID: PMC3326351. 3. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S, Kufe D. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 2011 May;10(5):806-16. PubMed Central PMCID: PMC3092019. 4. Panchamoorthy G, Fukazawa T, Stolz L, Payne G, Reedquist K, Shoelson S, Songyang Z, Cantley L, Walsh C, Band H. Physical and functional interactions between SH2 and SH3 domains of the Src family protein tyrosine kinase p59fyn. Mol Cell Biol. 1994 Sep;14(9):6372-85. PubMed Central PMCID: PMC359163. 5. Panchamoorthy G, Fukazawa T, Miyake S, Soltoff S, Reedquist K, Druker B, Shoelson S, Cantley L, Band H. p120cbl is a major substrate of tyrosine phosphorylation upon B cell antigen receptor stimulation and interacts in vivo with Fyn and Syk tyrosine kinases, Grb2 and Shc adaptors, and the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem. 1996 Feb 9;271(6):3187-94. PubMed PMID: 8621719. NIH BIOGRAPHICAL SKETCH SUPPLEMENT Name: Panchamoorthy, Govind Position Title: Vice President, Immuno-oncology Organization and Location: XYone Threpeutics, Canton, Massachusetts, United States Personal Statement I am a scientific leader with more than 25 years of drug discovery experience in pharmaceutical and biotech industry. I have played leadership roles in immuno-oncology projects pertaining to the development of antibody-based therapeutics, and target discovery/validation for cancer and inflammation drug discovery. Proven experience in basic research in immunological signal transduction that is translatable to understand the mechanism of oncogenesis and inflammation by src-family kinases. Broad expertise in assay development and validation for vaccine components and the release of vaccine products. Experienced molecular and cellular immunologist with proficiency in immune recognition and immune modulation. In addition to these scientific experiences, I have obtained several management trainings by